Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Associate Medical Professionals LLC

Neither a doctor nor a teaching hospital

Research payments

$1,307,514

25 payments

Through program year 2025, Associate Medical Professionals LLC is reported as receiving $1,307,514 in research payments, across 25 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $723,276 5
2024 Research $408,504 4
2023 Research $22,861 3
2022 Research $49,542 3
2021 Research $67,990 4
2020 Research $27,710 4
2019 Research $7,630 2

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $1,167,738 23 payments
  2. AstraZeneca UK Limited $139,776 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco $497,710 2 payments
  2. A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 $437,963 1 payment
  3. A Multi-arm, Open-label Phase I/IIa Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of AZD5305 in Combination with New Hormonal Agents in Patients with Metastatic Prostate Cancer (PETRANHA) $139,776 2 payments
  4. A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer $121,435 9 payments
  5. A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib Abiraterone Versus Placebo Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) $52,327 4 payments
  6. A Randomised,Double blind,Placebo controlled,Adaptive,Population Enrichment Phase III Study of AZD5305 in Men with Metastatic Castration sensitive Prostate Cancer Receiving Physician is Choice New Hormonal Agents $29,598 1 payment
  7. A Phase III Open Label Randomized Study to Assess the Efficacy and Safety of Olaparib Lynparza Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations PROfound $21,076 4 payments
  8. Study of Olaparib Lynparza Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration Resistant Prostate Cancer PROfound Study $7,630 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record